These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 39017931)

  • 1. Phage therapy: an alternative treatment modality for MDR bacterial infections.
    Pal N; Sharma P; Kumawat M; Singh S; Verma V; Tiwari RR; Sarma DK; Nagpal R; Kumar M
    Infect Dis (Lond); 2024 Oct; 56(10):785-817. PubMed ID: 39017931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibacterial effect of phage cocktails and phage-antibiotic synergy against pathogenic
    Zhao M; Li H; Gan D; Wang M; Deng H; Yang QE
    mSystems; 2024 Sep; 9(9):e0060724. PubMed ID: 39166877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial resistance: use of phage therapy in the management of resistant infections.
    Ikpe F; Williams T; Orok E; Ikpe A
    Mol Biol Rep; 2024 Aug; 51(1):925. PubMed ID: 39167154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy.
    Tagliaferri TL; Jansen M; Horz HP
    Front Cell Infect Microbiol; 2019; 9():22. PubMed ID: 30834237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zebrafish as an effective model for evaluating phage therapy in bacterial infections: a promising strategy against human pathogens.
    Plumet L; Costechareyre D; Lavigne J-P; Kissa K; Molle V
    Antimicrob Agents Chemother; 2024 Oct; 68(10):e0082924. PubMed ID: 39248472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Susceptibilities of multidrug-resistant pathogens responsible for complicated skin and soft tissue infections to standard bacteriophage cocktails].
    Gündoğdu A; Kılıç H; Ulu Kılıç A; Kutateladze M
    Mikrobiyol Bul; 2016 Apr; 50(2):215-23. PubMed ID: 27175494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phage therapy as strategy to face post-antibiotic era: a guide to beginners and experts.
    Royer S; Morais AP; da Fonseca Batistão DW
    Arch Microbiol; 2021 May; 203(4):1271-1279. PubMed ID: 33474609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacteriophage treatment as an alternative therapy for multidrug-resistant bacteria.
    Alqahtani A
    Saudi Med J; 2023 Dec; 44(12):1222-1231. PubMed ID: 38016738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacteriophages for ESKAPE: role in pathogenicity and measures of control.
    Patil A; Banerji R; Kanojiya P; Koratkar S; Saroj S
    Expert Rev Anti Infect Ther; 2021 Jul; 19(7):845-865. PubMed ID: 33261536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Systematic and Critical Review of Bacteriophage Therapy Against Multidrug-resistant ESKAPE Organisms in Humans.
    El Haddad L; Harb CP; Gebara MA; Stibich MA; Chemaly RF
    Clin Infect Dis; 2019 Jun; 69(1):167-178. PubMed ID: 30395179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential use of bacteriophages as antibacterial agents against Klebsiella pneumoniae.
    Gholizadeh O; Ghaleh HEG; Tat M; Ranjbar R; Dorostkar R
    Virol J; 2024 Aug; 21(1):191. PubMed ID: 39160541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of multidrug-resistant ESKAPEE pathogens from clinical samples in Chonburi, Thailand (2017-2018).
    Ruekit S; Srijan A; Serichantalergs O; Margulieux KR; Mc Gann P; Mills EG; Stribling WC; Pimsawat T; Kormanee R; Nakornchai S; Sakdinava C; Sukhchat P; Wojnarski M; Demons ST; Crawford JM; Lertsethtakarn P; Swierczewski BE
    BMC Infect Dis; 2022 Aug; 22(1):695. PubMed ID: 35978294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of Novel
    Mulani MS; Kumkar SN; Pardesi KR
    Microbiol Spectr; 2022 Dec; 10(6):e0199422. PubMed ID: 36374021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel antimicrobial agents for combating antibiotic-resistant bacteria.
    Chang RYK; Nang SC; Chan HK; Li J
    Adv Drug Deliv Rev; 2022 Aug; 187():114378. PubMed ID: 35671882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?
    Luong T; Salabarria AC; Roach DR
    Clin Ther; 2020 Sep; 42(9):1659-1680. PubMed ID: 32883528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phage Therapy: An Alternative Approach to Combating Multidrug-Resistant Bacterial Infections in Cystic Fibrosis.
    Cocorullo M; Stelitano G; Chiarelli LR
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125890
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Li S; Wei B; Xu L; Cong C; Murtaza B; Wang L; Li X; Li J; Xu M; Yin J; Xu Y
    J Virol; 2024 Jul; 98(7):e0046724. PubMed ID: 38864621
    [No Abstract]   [Full Text] [Related]  

  • 18. A Multiwell-Plate Caenorhabditis elegans Assay for Assessing the Therapeutic Potential of Bacteriophages against Clinical Pathogens.
    Manohar P; Loh B; Elangovan N; Loganathan A; Nachimuthu R; Leptihn S
    Microbiol Spectr; 2022 Feb; 10(1):e0139321. PubMed ID: 35171008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacteriophage Treatment: Critical Evaluation of Its Application on World Health Organization Priority Pathogens.
    Al-Ishaq RK; Skariah S; Büsselberg D
    Viruses; 2020 Dec; 13(1):. PubMed ID: 33396965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bacteriophages as a potential substitute for antibiotics: A comprehensive review.
    Kushwaha SO; Sahu SK; Yadav VK; Rathod MC; Patel D; Sahoo DK; Patel A
    Cell Biochem Funct; 2024 Apr; 42(3):e4022. PubMed ID: 38655589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.